Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
237
datasets available to search
ShareScore release 0.9.0
Dataset results
237 results for “mechanism of action”
An integrated approach including docking, MD simulations, and network analysis highlights the action mechanism of the cardiac hERG activator RPR260243
<p>500 ns MD trajectories of the hERG bound states (protein and ligand) used for the analyses discussed in the paper. There are three replica for each system. The trajectories can be visualized using molecular visualization programs such as Pymol or VMD uploading the PDB and the DCD file.</p> <p>The PDB and the topology files of the hERG bound state (protein, membrane, ions and ligand) are also included.</p> <p>An example of input file used for the production step of the dynamics has been provided (production_1.conf). </p>
Mechanism and site of action of big dynorphin on ASIC1a
<p>Contains a read_me file and data related to the publication: Mechanism and site of action of big dynorphin on ASIC1a</p>
Drug Mechanism of Action Target Database
<p>First release contains data from March 2016 release of DrugCentral database.</p>
Computational mechanisms underlying latent value updating of unchosen actions
<p><span>Current studies suggest that individuals estimate the value of their choices based on observed feedback. Here, we ask whether individuals also update the value of their unchosen actions, even when the associated feedback remains unknown. </span><span>One hundred and seventy-eight</span><span> individuals completed a multi-armed bandit task, making choices to gain rewards. We found robust evidence suggesting latent value updating of unchosen actions based on the chosen action's outcome. Computational modeling results suggested that this effect is mainly explained by a value updating mechanism whereby individuals integrate the outcome history for choosing an option with that of rejecting the alternative. Properties of the deliberation (i.e., duration/difficulty) did not moderate the latent value updating of unchosen actions, suggesting that memory traces generated during deliberation might take a smaller role in this specific phenomenon than previously thought. We discuss the mechanisms facilitating credit assignment to unchosen actions and their implications for human decision-making.</span></p>
Computational mechanisms underlying latent value updating of unchosen actions
Open the record for dataset details and reuse information.
Database of mechanism of action paths for selected drug-disease indications
<p>Mechanistic paths that lead from drug to disease in a heterogeneous network.</p> <p>Version 1.1.0 includes a new tab `metapaths_biolink` where the majority of node and edge types have been mapped to entities and relationship slots in the <a href="https://biolink.github.io/biolink-model/">biolink model.</a> Concepts unable to be mapped at this time are represented in ALL CAPS.</p> <p>JSON version of the paths available <a href="https://github.com/SuLab/indication_moa_db/tree/1.0">on GitHub</a></p>
COVID-CDR: An integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action
<p>Repurposing of the existing medications has become the mainstream focus of anti-COVID-19 drug discovery as it offers rapid and cost-effective solutions for therapeutic development. However, a great effort is still required to enhance the efficacy of repurposing therapeutic options through combination therapy, in which promising drugs with varying mechanisms of action are administered together. Nonetheless, our ability to identify and validate effective combinations is limited due to the vast number of possible drug pairs. Yet, there is no <span>available resource that</span> <span>can systematically guide to identify or choose the effective individual drugs or best possible synergistic drug combinations for the treatment of SARS-CoV</span>-<span>2 infection.</span> To address this resource gap<span>, we </span>developed <span>a web-based platform that displays the network-based mechanism of action of drug combinations, thus simultaneously </span>providing <span>a visual of the cellular interactome involved in modes of action of the chosen drugs. The platform allows the freedom to </span>select <span>two or more drug combinations and provides the options to investigate the network-based efficacy of drug combinations and understand the similarity score, primary indications, and pairwise synergistic scores on different cell-lines. In a nutshell, the platform (accessible via </span><a href="http://vafaeelab.com/COVID19_repositioning.html"><span>http://vafaeelab.com/COVID19_repositioning.html</span></a><span>) is the first of its type, which provides a systematic approach for pre-clinical investigation of combination therapy for treating COVID-19 at the fingertips of the clinicians or researchers.</span></p>
Different types of kinase inhibitors with experimentally confirmed mechanism of action
<p>A data set of ATP-competitive and allosteric inhibitors of human protein kinases with mechanisms of action confirmed by X-ray crystallography is provided. Data were acquired from the Protein Data Bank (PDB) and the KLIFS, ProfKin, ASD, and ChEMBL databases, curated, and organized. The composition of the data set is detailed in the accompanying readme.txt file.</p> <p> </p> <p> </p>
Mechanism of Praziquantel action at a parasitic flatworm ion channel
<p>Data supporting Park <em>et al.</em> [Mechanism of praziquantel action at a parasitic flatworm ion channel]</p> <p> </p>
Supplemental material to 'A variational rigid-block modelling approach to nonlinear elastic and kinematic analysis of failure mechanisms in historic masonry structures subjected to lateral actions'
<p>This repository contains the data necessary to reproduce the content of the article:</p> <blockquote> <p>A variational rigid-block modelling approach to nonlinear elastic and kinematic analysis of failure mechanisms in historic masonry structures subjected to lateral actions (2021). Earthquake Engineering & Structural Dynamics, 1–23. <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/eqe.3512">https://doi.org/10.1002/eqe.3512</a></p> </blockquote> <p>The file <strong>01_Dataset.zip</strong> contains the dataset. The companion document <strong>00_Dataset_description.pdf </strong>describes the content of the dataset, guiding the analyst to its use in order to (i) reproduce the article's results and (ii) compare the article's results to new results brought by the analyst, e.g. by comparison with other numerical models.</p> <p>Version history</p> <p>v2: updated references in 00_dataset description.pdf </p>
Datasets for Application of particle swarm optimization to understand the mechanism of action of allosteric inhibitors of the enzyme HSD17ß13
<p>Datasets used in the publication '</p> <p>Application of particle swarm optimization to understand the</p> <p>mechanism of action of allosteric inhibitors of the enzyme HSD17ß13'</p>
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT01710046. IPD Sharing: Not stated. Countries: 1. Publications: 2.
mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms
ClinicalTrials.gov study NCT01611194. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Mechanism of Action Study for Psoriasis
ClinicalTrials.gov study NCT00932113. IPD Sharing: NO. Countries: 1. Publications: 7.
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
ClinicalTrials.gov study NCT04271202. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
ClinicalTrials.gov study NCT00976599. IPD Sharing: Not stated. Countries: 1. Publications: 12.
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
ClinicalTrials.gov study NCT02688985. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Mechanisms of Action and Outcome
ClinicalTrials.gov study NCT00555568. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD
ClinicalTrials.gov study NCT05621174. IPD Sharing: NO. Countries: 1. Publications: 17.
Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation
ClinicalTrials.gov study NCT00956020. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.